ESR1 and breast cancer: The classification of BC into molecular subtypes—luminal A, luminal B, HER2-enriched, and triple-negative BC (TNBC)—based on biomarkers like estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), directs therapeutic strategies.